New combo therapy targets Hard-to-Treat liver and stomach cancers
NCT ID NCT03259867
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a two-step treatment for people with advanced liver cancer (hepatocellular carcinoma) or metastatic stomach cancer that has worsened despite prior immunotherapy. First, doctors deliver a drug called tirapazamine directly into the liver tumor through a procedure called TATE (transarterial embolization). Then, patients receive the immunotherapy drug nivolumab (Opdivo) to boost the immune system. The goal is to see if this combination can shrink tumors or slow disease progression. About 54 adults aged 18 to 80 will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tirapazamine embolization plus nivolumab
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with advanced liver or gastric cancer who have stopped responding to immunotherapy.
- What could go wrong
- This is an early phase 2 trial with only 54 participants, so results may not apply to everyone. The treatment involves a procedure and a drug, which may cause side effects or not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
University of California, Irvine
RECRUITINGOrange, California, 92868, United States
-
University of Oklahoma Health Science Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication